Northern Trust Corp Lexicon Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,144,031 shares of LXRX stock, worth $949,545. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,144,031
Previous 997,528 14.69%
Holding current value
$949,545
Previous $1.68 Million 7.22%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$1.51 - $2.39 $221,219 - $350,142
146,503 Added 14.69%
1,144,031 $1.8 Million
Q2 2024

Aug 14, 2024
BUY
$1.54 - $2.28 $201,696 - $298,616
130,972 Added 15.11%
997,528 $1.68 Million
Q1 2024

May 14, 2024
BUY
$1.3 - $3.58 $9,058 - $24,945
6,968 Added 0.81%
866,556 $2.08 Million
Q4 2023

Feb 13, 2024
SELL
$1.0 - $1.53 $291,229 - $445,580
-291,229 Reduced 25.31%
859,588 $1.32 Million
Q3 2023

Nov 13, 2023
BUY
$1.06 - $2.33 $73,125 - $160,737
68,986 Added 6.38%
1,150,817 $1.25 Million
Q2 2023

Aug 11, 2023
BUY
$2.15 - $3.49 $684,919 - $1.11 Million
318,567 Added 41.74%
1,081,831 $2.48 Million
Q1 2023

May 15, 2023
SELL
$1.99 - $2.68 $47,176 - $63,534
-23,707 Reduced 3.01%
763,264 $1.85 Million
Q4 2022

Feb 13, 2023
BUY
$1.8 - $2.56 $92,629 - $131,740
51,461 Added 7.0%
786,971 $1.5 Million
Q3 2022

Nov 14, 2022
BUY
$1.94 - $3.43 $122,311 - $216,251
63,047 Added 9.38%
735,510 $1.77 Million
Q2 2022

Aug 12, 2022
BUY
$1.31 - $2.69 $15,794 - $32,433
12,057 Added 1.83%
672,463 $1.25 Million
Q1 2022

May 13, 2022
SELL
$1.95 - $3.89 $54,541 - $108,803
-27,970 Reduced 4.06%
660,406 $1.38 Million
Q4 2021

Feb 08, 2022
BUY
$3.81 - $6.16 $1,135 - $1,835
298 Added 0.04%
688,376 $2.71 Million
Q3 2021

Nov 15, 2021
SELL
$3.38 - $5.35 $134,922 - $213,561
-39,918 Reduced 5.48%
688,078 $3.31 Million
Q2 2021

Aug 13, 2021
BUY
$4.12 - $5.87 $542,871 - $773,460
131,765 Added 22.1%
727,996 $3.34 Million
Q1 2021

May 12, 2021
BUY
$3.45 - $9.09 $194,704 - $513,003
56,436 Added 10.46%
596,231 $3.5 Million
Q4 2020

Feb 11, 2021
BUY
$1.05 - $3.67 $892 - $3,119
850 Added 0.16%
539,795 $1.85 Million
Q3 2020

Nov 16, 2020
SELL
$1.44 - $2.1 $29,096 - $42,432
-20,206 Reduced 3.61%
538,945 $776,000
Q2 2020

Aug 14, 2020
SELL
$1.75 - $2.3 $39,196 - $51,515
-22,398 Reduced 3.85%
559,151 $1.12 Million
Q1 2020

May 14, 2020
BUY
$1.8 - $4.28 $86,410 - $205,465
48,006 Added 9.0%
581,549 $1.13 Million
Q4 2019

Feb 14, 2020
BUY
$3.16 - $5.15 $28,762 - $46,875
9,102 Added 1.74%
533,543 $2.21 Million
Q3 2019

Nov 13, 2019
SELL
$1.2 - $6.66 $37,306 - $207,052
-31,089 Reduced 5.6%
524,441 $1.58 Million
Q2 2019

Aug 13, 2019
SELL
$5.35 - $7.11 $204,915 - $272,327
-38,302 Reduced 6.45%
555,530 $3.49 Million
Q1 2019

May 13, 2019
SELL
$4.36 - $7.94 $52,023 - $94,740
-11,932 Reduced 1.97%
593,832 $3.3 Million
Q4 2018

Feb 12, 2019
SELL
$6.15 - $10.51 $76,745 - $131,154
-12,479 Reduced 2.02%
605,764 $4.02 Million
Q3 2018

Nov 14, 2018
BUY
$10.32 - $13.06 $349,332 - $442,081
33,850 Added 5.79%
618,243 $6.6 Million
Q2 2018

Sep 18, 2018
SELL
$7.8 - $13.69 $53,157 - $93,297
-6,815 Reduced 1.15%
584,393 $7.01 Million
Q2 2018

Aug 14, 2018
BUY
$7.8 - $13.69 $149,011 - $261,533
19,104 Added 3.34%
591,208 $7.1 Million
Q1 2018

May 09, 2018
SELL
$7.86 - $11.39 $158,811 - $230,134
-20,205 Reduced 3.41%
572,104 $4.9 Million
Q4 2017

Feb 14, 2018
SELL
$8.77 - $12.28 $66,485 - $93,094
-7,581 Reduced 1.26%
592,309 $5.85 Million
Q3 2017

Nov 13, 2017
BUY
$12.17 - $16.3 $7.3 Million - $9.78 Million
599,890
599,890 $7.37 Million

Others Institutions Holding LXRX

# of Institutions
141
Shares Held
238M
Call Options Held
459K
Put Options Held
133K
View Full List

About LEXICON PHARMACEUTICALS, INC.

LXRX Quotes by TradingView
  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $157M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email